SEARCH

SEARCH BY CITATION

References

  • 1
    Podolsky DK. Inflammatory bowel disease. N Engl J Med 2002; 347: 41729.
  • 2
    Sands BE. Therapy of inflammatory bowel disease. Gastroenterology 2000; 118 (2 Suppl. 1): S6882.
  • 3
    Tiede I, Fritz G, Strand S, et al. CD28-dependent Rac1 activation is the molecular target of azathioprine in primary human CD4+ T lymphocytes. J Clin Invest 2003; 111: 113345.
  • 4
    Crawford DJ, Maddocks JL, Jones DN, Szawlowski P. Rational design of novel immunosuppressive drugs: analogues of azathioprine lacking the 6-mercaptopurine substituent retain or have enhanced immunosuppressive effects. J Med Chem 1996; 39: 26905.
  • 5
    Stevens T, Achkar JP, Easley K, Brzezinski A, Lashner B. Azathioprine formulation optimizes metabolite profile in inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20: 6016.
  • 6
    Rhodes J, Bainton D, Beck P, Campbell H. Controlled trial of azathioprine in Crohn's disease. Lancet 1971; 2: 12736.
  • 7
    Willoughby JM, Beckett J, Kumar PJ, Dawson AM. Controlled trial of azathioprine in Crohn's disease. Lancet 1971; 2: 9447.
  • 8
    Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn's disease. A meta-analysis. Ann Intern Med 1995; 123: 13242.
  • 9
    Kirk AP, Lennard-Jones JE. Controlled trial of azathioprine in chronic ulcerative colitis. Br Med J (Clin Res Ed) 1982; 284: 12912.
  • 10
    Hawthorne AB, Logan RF, Hawkey CJ, et al. Randomised controlled trial of azathioprine withdrawal in ulcerative colitis. BMJ 1992; 305: 202.
  • 11
    Lemann M, Bouthnik Y, Colombel J, et al. Randomized, double-blind, placebo-controlled, multicenter, azathioprine (AZA) withdrawal trial in Crohn's disease (CD). Gastroenterology 2002; 122: A23.
  • 12
    Kim PS, Zlatanic J, Korelitz BI, Gleim GW. Optimum duration of treatment with 6-mercaptopurine for Crohn's disease. Am J Gastroenterol 1999; 94: 32547.
    Direct Link:
  • 13
    George J, Present DH, Pou R, Bodian C, Rubin PH. The long-term outcome of ulcerative colitis treated with 6-mercaptopurine. Am J Gastroenterol 1996; 91: 17114.
  • 14
    Lobel EZ, Korelitz BI, Xuereb MA, Panagopoulos G. A search for the optimal duration of treatment with 6-mercaptopurine for ulcerative colitis. Am J Gastroenterol 2004; 99: 4625.
    Direct Link:
  • 15
    Treton X, Bouhnik Y, Mary J, et al. Azathioprine withdrawal in patients with Crohn's disease (CD) maintained on prolonged remission under treatment is associated with a high risk of relapse. Gastroenterology 2004; 126: A113.
  • 16
    Present DH, Meltzer SJ, Krumholz MP, Wolke A, Korelitz BI. 6-Mercaptopurine in the management of inflammatory bowel disease: short- and long-term toxicity. Ann Intern Med 1989; 111: 6419.
  • 17
    Bouhnik Y, Lemann M, Mary JY, et al. Long-term follow-up of patients with Crohn's disease treated with azathioprine or 6-mercaptopurine. Lancet 1996; 347 (8996): 2159.
  • 18
    de Jong DJ, Goullet M, Naber TH. Side effects of azathioprine in patients with Crohn's disease. Eur J Gastroenterol Hepatol 2004; 16: 20712.
  • 19
    Khan ZH, Mayberry JF, Spiers N, Wicks AC. Retrospective case series analysis of patients with inflammatory bowel disease on azathioprine. A district general hospital experience. Digestion 2000; 62: 24954.
  • 20
    O'Brien JJ, Bayless TM, Bayless JA. Use of azathioprine or 6-mercaptopurine in the treatment of Crohn's disease. Gastroenterology 1991; 101: 3946.
  • 21
    Warman JI, Korelitz BI, Fleisher MR, Janardhanam R. Cumulative experience with short- and long-term toxicity to 6-mercaptopurine in the treatment of Crohn's disease and ulcerative colitis. J Clin Gastroenterol 2003; 37: 2205.
  • 22
    Connell WR, Kamm MA, Ritchie JK, Lennard-Jones JE. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993; 34: 10815.
  • 23
    Lemyze M, Tavernier JY, Chevalon B, Lamblin C. Severe varicella zoster pneumonia during the course of treatment with azathioprine for Crohn's disease. Rev Mal Respir 2003; 20 (5 Pt 1): 7736.
  • 24
    Vergara M, Brullet E, Campo R, Calvet X, Blanch L. Fulminant infection caused by varicella herpes zoster in patient with Crohn's disease undergoing treatment with azathioprine. Gastroenterol Hepatol 2001; 24: 47.
  • 25
    Hookey LC, Depew W, Boag A, Vanner S. 6-Mercaptopurine and inflammatory bowel disease: hidden ground for the cytomegalovirus. Can J Gastroenterol 2003; 17: 31922.
  • 26
    Siegel C, Olenec C, Wartman D, Bensen S, Ely P. Hemophagocytic syndrome: a complication of ulcerative colitis or side-effect of 6-MP therapy? Am J Gastroenterol 2004; 99: S134.
  • 27
    Posthuma EF, Westendorp RG, van der Sluys Veer A, Kluin-Nelemans JC, Kluin PM, Lamers CB. Fatal infectious mononucleosis: a severe complication in the treatment of Crohn's disease with azathioprine. Gut 1995; 36: 3113.
  • 28
    Fraser AG, Orchard TR, Robinson EM, Jewell DP. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther 2002; 16: 122532.
  • 29
    Loftus EV Jr, Tremaine WJ, Habermann TM, Harmsen WS, Zinsmeister AR, Sandborn WJ. Risk of lymphoma in inflammatory bowel disease. Am J Gastroenterol 2000; 95: 230812.
    Direct Link:
  • 30
    Lewis JD, Schwartz JS, Lichtenstein GR. Azathioprine for maintenance of remission in Crohn's disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000; 118: 101824.
  • 31
    Dayharsh GA, Loftus EV Jr, Sandborn WJ, et al. Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurine. Gastroenterology 2002; 122: 727.
  • 32
    Connell WR, Kamm MA, Dickson M, Balkwill AM, Ritchie JK, Lennard-Jones JE. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 1994; 343: 124952.
  • 33
    Alloub MI, Barr BB, McLaren KM, Smith IW, Bunney MH, Smart GE. Human papillomavirus infection and cervical intraepithelial neoplasia in women with renal allografts. BMJ 1989; 298: 1536.
  • 34
    Halpert R, Fruchter RG, Sedlis A, Butt K, Boyce JG, Sillman FH. Human papillomavirus and lower genital neoplasia in renal transplant patients. Obstet Gynecol 1986; 68: 2518.
  • 35
    McLelland J, Rees A, Williams G, Chu T. The incidence of immunosuppression-related skin disease in long-term transplant patients. Transplantation 1988; 46: 8714.
  • 36
    Austin AS, Spiller RC. Inflammatory bowel disease, azathioprine and skin cancer: case report and literature review. Eur J Gastroenterol Hepatol 2001; 13: 1934.
  • 37
    Ansari A, Soon S, Lindsay J, et al. Thiopurine methyl transferase activity predicts both toxicity and clinical response to azathioprine in inflammatory bowel disease: the London IBD forum prospective study. Gastroenterology 2004; 126: A463.
  • 38
    Dubinsky MC, Lamothe S, Yang HY, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118: 70513.
  • 39
    Otterness D, Szumlanski C, Lennard L, et al. Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms. Clin Pharmacol Ther 1997; 62: 6073.
  • 40
    Lennard L. TPMT in the treatment of Crohn's disease with azathioprine. Gut 2002; 51: 1436.
  • 41
    Winter J, Walker A, Shapiro D, Gaffney D, Spooner RJ, Mills PR. Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20: 5939.
  • 42
    Colombel JF, Ferrari N, Debuysere H, et al. Genotypic analysis of thiopurine S-methyltransferase in patients with Crohn's disease and severe myelosuppression during azathioprine therapy. Gastroenterology 2000; 118: 102530.
  • 43
    Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997; 126: 60814.
  • 44
    Cuffari C, Dassopoulos T, Turnbough L, Thompson RE, Bayless TM. Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol 2004; 2: 4107.
  • 45
    Elion G. The comparative metabolism of Imuran and 6-mercaptopurine in man. Proc Am Assoc Cancer Res 1969; 10: 21.
  • 46
    Sandborn WJ. A review of immune modifier therapy for inflammatory bowel disease: azathioprine, 6-mercaptopurine, cyclosporine, and methotrexate. Am J Gastroenterol 1996; 91: 42333.
  • 47
    Rayner CK, Hart AL, Hayward CM, Emmanuel AV, Kamm MA. Azathioprine dose escalation in inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20: 6571.
  • 48
    Cuffari C, Hunt S, Bayless TM. Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy. Aliment Pharmacol Ther 2000; 14: 100914.
  • 49
    Colonna T, Korelitz BI. The role of leukopenia in the 6-mercaptopurine-induced remission of refractory Crohn's disease. Am J Gastroenterol 1994; 89: 3626.
  • 50
    Sandborn WJ, Van OE, Zins BJ, Tremaine WJ, Mays DC, Lipsky JJ. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology 1995; 109: 180817.
  • 51
    Cuffari C, Theoret Y, Latour S, Seidman G. 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity. Gut 1996; 39: 4016.
  • 52
    DiSanti W, Rajapakse R, Korelitz B, Panagopoulos G, Furer S, Janamillo-Nieves L. Increased incidence of neoplasms in patients who develop sustained leukopenia during or after treatment with 6MP for inflammatory bowel disease. Am J Gastroenterol 2004; 99: S252.
  • 53
    Sandborn WJ, Tremaine WJ, Wolf DC, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology 1999; 117: 52735.
  • 54
    Castiglione F, Del Vecchio Blanco G, Rispo A, Mazzacca G. Prevention of pancreatitis by weekly amylase assay in patients with Crohn's disease treated with azathioprine. Am J Gastroenterol 2000; 95: 23945.
    Direct Link:
  • 55
    Cohen RD. Forecast for using metabolite measurements in the dosing of azathioprine or 6-mercaptopurine for IBD patients: ‘partly cloudy’. Gastroenterology 2002; 122: 20824; discussion 2084.
  • 56
    Cuffari C, Hunt S, Bayless T. Utilisation of erythrocyte 6-thioguanine metabolite levels to optimise azathioprine therapy in patients with inflammatory bowel disease. Gut 2001; 48: 6426.
  • 57
    Seidman EG, Theoret Y, Fisher R, Seidman J, Amre O. Thiopurine drug metabolite levels guide treatment in ulcerative colitis. Gastroenterology 2004; 126: A209.
  • 58
    Lowry PW, Franklin CL, Weaver AL, et al. Measurement of thiopurine methyltransferase activity and azathioprine metabolites in patients with inflammatory bowel disease. Gut 2001; 49: 66570.
  • 59
    Reuther LO, Sonne J, Larsen NE, et al. Pharmacological monitoring of azathioprine therapy. Scand J Gastroenterol 2003; 38: 9727.
  • 60
    Wright S, Sanders DS, Lobo AJ, Lennard L. Clinical significance of azathioprine active metabolite concentrations in inflammatory bowel disease. Gut 2004; 53: 11238.
  • 61
    Dubinsky MC, Hassard PV, Seidman EG, et al. An open-label pilot study using thioguanine as a therapeutic alternative in Crohn's disease patients resistant to 6-mercaptopurine therapy. Inflamm Bowel Dis 2001; 7: 1819.
  • 62
    Goldenberg BA, Rawsthorne P, Bernstein CN. The utility of 6-thioguanine metabolite levels in managing patients with inflammatory bowel disease. Am J Gastroenterol 2004; 99: 17448.
    Direct Link:
  • 63
    Dubinsky MC, Yang H, Hassard PV, et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology 2002; 122: 90415.
  • 64
    Lichtenstein GR. Use of laboratory testing to guide 6-mercaptopurine/azathioprine therapy. Gastroenterology 2004; 127: 155864.
  • 65
    Marinaki AM, Ansari A, Duley JA, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004; 14: 1817.
  • 66
    Ansari A, Soon S, Raoof S, et al. Pharmacogenetic profiling in azathioprine therapy: the role of TPMT, ITPA and MTHFR polymorphisms in drug therapy. Gastroenterology 2004; 126: A215.
  • 67
    Zelinkova Z, Derrijks L, Stokkers P, et al. Inosine triphosphate pyrophosphatase gene mutation predicts myelosuppression in IBD patients treated with azathioprine. Gastroenterology 2004; 126: A112.
  • 68
    Lewis LD, Benin A, Szumlanski CL, et al. Olsalazine and 6-mercaptopurine-related bone marrow suppression: a possible drug-drug interaction. Clin Pharmacol Ther 1997; 62: 46475.
  • 69
    Izumiya M, Yoshizawa S, Yajima T, et al. 6-MP metabolite interacts with purine analogs in patients with inflammatory bowel disease. Gastroenterology 2004; 126: A631.
  • 70
    Achkar JP, Brzezinski A, Lashner B, Vogel D, Seidner D, Shen B. A double-blind, placebo-controlled randomized clinical trial evaluating the effects of sulfasalazine on 6-mercaptopurine metabolism in patients with Crohn's disease. Am J Gastroenterol 2004; 99: S264.
  • 71
    Roblin X, Serre-Debeauvais F, Phelip JM, Bessard G, Bonaz B. Drug interaction between infliximab and azathioprine in patients with Crohn's disease. Aliment Pharmacol Ther 2003; 18: 91725.
  • 72
    Lysaa RA, Giverhaug T, Wold HL, Aarbakke J. Inhibition of human thiopurine methyltransferase by furosemide, bendroflumethiazide and trichlormethiazide. Eur J Clin Pharmacol 1996; 49: 3936.
  • 73
    Feagan BG, Alfadhli A. Methotrexate in inflammatory bowel disease. Gastroenterol Clin North Am 2004; 33: 40720.
  • 74
    Cutolo M, Sulli A, Pizzorni C, Seriolo B, Straub RH. Anti-inflammatory mechanisms of methotrexate in rheumatoid arthritis. Ann Rheum Dis 2001; 60: 72935.
  • 75
    Seitz M. Molecular and cellular effects of methotrexate. Curr Opin Rheumatol 1999; 11: 22632.
  • 76
    Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995; 332: 2927.
  • 77
    Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000; 342: 162732.
  • 78
    Paoluzi OA, Pica R, Marcheggiano A, et al. Azathioprine or methotrexate in the treatment of patients with steroid-dependent or steroid-resistant ulcerative colitis: results of an open-label study on efficacy and tolerability in inducing and maintaining remission. Aliment Pharmacol Ther 2002; 16: 17519.
  • 79
    Oren R, Arber N, Odes S, et al. Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996; 110: 141621.
  • 80
    Mate-Jimenez J, Hermida C, Cantero-Perona J, Moreno-Otero R. 6-Mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000; 12: 122733.
  • 81
    Cummings JRF, Herrlinger KR, Travis SPL, Gorard DA, McIntyre AS, Jewell DP. Oral methotrexate in ulcerative colitis. Aliment Pharmacol Ther 2005; 21: 3859.
  • 82
    Kozarek RA, Patterson DJ, Gelfand MD, Botoman VA, Ball TJ, Wilske KR. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989; 110: 3536.
  • 83
    Malatjalian DA, Ross JB, Williams CN, Colwell SJ, Eastwood BJ. Methotrexate hepatotoxicity in psoriatics: report of 104 patients from Nova Scotia, with analysis of risks from obesity, diabetes and alcohol consumption during long term follow-up. Can J Gastroenterol 1996; 10: 36975.
  • 84
    Te HS, Schiano TD, Kuan SF, Hanauer SB, Conjeevaram HS, Baker AL. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 2000; 95: 31506.
    Direct Link:
  • 85
    Roenigk HH Jr, Auerbach R, Maibach HI, Weinstein GD. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1988; 19 (1 Pt 1): 14556.
  • 86
    Alarcon GS, Kremer JM, Macaluso M, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med 1997; 127: 35664.
  • 87
    Bohon P, Dugernier T, Debongnie JC, Pirenne B. Hypersensitivity interstitial pneumopathy and ulcero-hemorrhagic rectocolitis: role of methotrexate. Acta Gastroenterol Belg 1993; 56: 3527.
  • 88
    Sussman A, Leonard JM. Psoriasis, methotrexate, and oligospermia. Arch Dermatol 1980; 116: 2157.
  • 89
    Morris LF, Harrod MJ, Menter MA, Silverman AK. Methotrexate and reproduction in men: case report and recommendations. J Am Acad Dermatol 1993; 29 (5 Pt 2): 9136.
  • 90
    Oren R, Moshkowitz M, Odes S, et al. Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 1997; 92: 22039.
  • 91
    Arora S, Katkov W, Cooley J, et al. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology 1999; 46: 17249.
  • 92
    Moshkowitz M, Oren R, Tishler M, et al. The absorption of low-dose methotrexate in patients with inflammatory bowel disease. Aliment Pharmacol Ther 1997; 11: 56973.
  • 93
    Kurnik D, Loebstein R, Fishbein E, et al. Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn's disease. Aliment Pharmacol Ther 2003; 18: 5763.
  • 94
    Hamilton RA, Kremer JM. Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997; 36: 8690.
  • 95
    Brooks PJ, Spruill WJ, Parish RC, Birchmore DA. Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. Arthritis Rheum 1990; 33: 914.
  • 96
    Ardizzone S, Bollani S, Manzionna G, Imbesi V, Colombo E, Bianchi Porro G. Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn's disease: a randomised, investigator-blind study. Dig Liver Dis 2003; 35: 61927.
  • 97
    Al-Awadhi A, Dale P, McKendry RJ. Pancytopenia associated with low dose methotrexate therapy. A regional survey. J Rheumatol 1993; 20: 11215.
  • 98
    Bannwarth B, Pehourcq F, Schaeverbeke T, Dehais J. Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis. Clin Pharmacokinet 1996; 30: 194210.
  • 99
    Kremer JM, Alarcon GS, Lightfoot RW Jr, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994; 37: 31628.
  • 100
    Aithal GP, Haugk B, Das S, Card T, Burt AD, Record CO. Monitoring methotrexate-induced hepatic fibrosis in patients with psoriasis: are serial liver biopsies justified? Aliment Pharmacol Ther 2004; 19: 3919.
  • 101
    Urano W, Taniguchi A, Yamanaka H, et al. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 2002; 12: 18390.
  • 102
    Ulrich CM, Yasui Y, Storb R, et al. Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 2001; 98: 2314.
  • 103
    Soon S, Ansari A, Marinaki T, Arenas M, Magdalinou K, Sanderson J. C677T and A1298C methylenetetrahydrofolate reductase (MTHFR) gene polymorphisms does not predict toxicity or efficacy of methotrexate in patients with inflammatory bowel disease. Gastroenterology 2004; 126: A210.
  • 104
    Haagsma CJ, Blom HJ, van Riel PL, et al. Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis 1999; 58: 7984.
  • 105
    Nakano E, Taylor CJ, Chada L, McGaw J, Powers HJ. Hyperhomocystinemia in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2003; 37: 58690.
  • 106
    Papa A, De Stefano V, Danese S, et al. Hyperhomocysteinemia and prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients with inflammatory bowel disease. Am J Gastroenterol 2001; 96: 267782.
    Direct Link:
  • 107
    Kader HA, Berman WF, Al-Seraihy AS, Ware RE, Ulshen MH, Treem WR. Prevalence of factor V G1691A (Leiden), prothrombin G20210A, and methylene tetrahydrofolate reductase C677T thrombophilic mutations in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2002; 35: 62935.
  • 108
    Bjerregaard LT, Nederby NJ, Fredholm L, Brandslund I, Munkholm P, Hey H. Hyperhomocysteinaemia, coagulation pathway activation and thrombophilia in patients with inflammatory bowel disease. Scand J Gastroenterol 2002; 37: 627.
  • 109
    Vecchi M, Sacchi E, Saibeni S, et al. Inflammatory bowel diseases are not associated with major hereditary conditions predisposing to thrombosis. Dig Dis Sci 2000; 45: 14659.
  • 110
    van Ede AE, Laan RF, Blom HJ, et al. Homocysteine and folate status in methotrexate-treated patients with rheumatoid arthritis. Rheumatology (Oxford) 2002; 41: 65865.
  • 111
    Chan ES, Cronstein BN. Molecular action of methotrexate in inflammatory diseases. Arthritis Res 2002; 4: 26673.
  • 112
    Gerber DA, Bonham CA, Thomson AW. Immunosuppressive agents: recent developments in molecular action and clinical application. Transplant Proc 1998; 30: 15739.
  • 113
    Brynskov J, Freund L, Rasmussen SN, et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med 1989; 321: 84550.
  • 114
    Brynskov J, Freund L, Norby Rasmussen S, et al. Final report on a placebo-controlled, double-blind, randomized, multicentre trial of cyclosporin treatment in active chronic Crohn's disease. Scand J Gastroenterol 1991; 26: 68995.
  • 115
    Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994; 330: 18415.
  • 116
    Kornbluth A, Lichtiger S, Present D, et al. Long-term results of oral cyclosporine in patients with severe ulcerative colitis: a double-blind, randomized, multicenter trial. Gastroenterology 1994; 106: A714.
  • 117
    Cohen RD, Stein R, Hanauer SB. Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 1999; 94: 158792.
    Direct Link:
  • 118
    Fernandez-Banares F, Bertran X, Esteve-Comas M, et al. Azathioprine is useful in maintaining long-term remission induced by intravenous cyclosporine in steroid-refractory severe ulcerative colitis. Am J Gastroenterol 1996; 91: 24989.
  • 119
    Sandborn W. A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis 1995; 1: 4863.
  • 120
    Loftus CG, Egan LJ, Sandborn WJ. Cyclosporine, tacrolimus, and mycophenolate mofetil in the treatment of inflammatory bowel disease. Gastroenterol Clin North Am 2004; 33: 14169.
  • 121
    Feutren G, Mihatsch MJ. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. N Engl J Med 1992; 326: 165460.
  • 122
    de Groen PC, Aksamit AJ, Rakela J, Forbes GS, Krom RA. Central nervous system toxicity after liver transplantation. The role of cyclosporine and cholesterol. N Engl J Med 1987; 317: 8616.
  • 123
    Thompson CB, June CH, Sullivan KM, Thomas ED. Association between cyclosporin neurotoxicity and hypomagnesaemia. Lancet 1984; 2: 111620.
  • 124
    Barton CH, Vaziri ND, Martin DC, Choi S, Alikhani S. Hypomagnesemia and renal magnesium wasting in renal transplant recipients receiving cyclosporine. Am J Med 1987; 83: 6939.
  • 125
    Van Assche G, D'Haens G, Noman M, et al. Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003; 125: 102531.
  • 126
    Kornbluth A, Present DH, Lichtiger S, Hanauer S. Cyclosporin for severe ulcerative colitis: a user's guide. Am J Gastroenterol 1997; 92: 14248.
  • 127
    Flanagan WM, Corthesy B, Bram RJ, Crabtree GR. Nuclear association of a T-cell transcription factor blocked by FK-506 and cyclosporin A. Nature 1991; 352: 8037.
  • 128
    Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology 2003; 125: 3808.
  • 129
    Lowry PW, Weaver AL, Tremaine WJ, Sandborn WJ. Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae. Inflamm Bowel Dis 1999; 5: 23945.
  • 130
    Ierardi E, Principi M, Francavilla R, et al. Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance. Aliment Pharmacol Ther 2001; 15: 3717.
  • 131
    Gonzalez Lama Y, Abreu LE, Vera MI, et al. Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn's disease. Inflamm Bowel Dis 2005; 111: 815.
  • 132
    Bousvaros A, Kirschner BS, Werlin SL, et al. Oral tacrolimus treatment of severe colitis in children. J Pediatr 2000; 137: 7949.
  • 133
    Baumgart DC, Wiedenmann B, Dignass AU. Rescue therapy with tacrolimus is effective in patients with severe and refractory inflammatory bowel disease. Aliment Pharmacol Ther 2003; 17: 127381.